Somatostatin Analog SMS 201-995 and Insulin Needs in Insulin-Dependent Diabetic Patients Studied by Means of an Artificial Pancreas*

Rios, Serrano M.; Navascués, I.; Sabán, J.; Ordóñez, Ángel; Sevilla, F.; Pozo, D. del

doi:10.1210/jcem-63-5-1071

Cited by 35 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatostatin also inhibits insulin clearance (30). Octreotide reduces insulin requirements in type I diabetic patients (31,32) without adversely affecting blood glucose levels in type II patients (33). Our patients with IGT at baseline did not experience a worsening in their glucose tolerance any more frequently than those with normal baseline glucose tolerance.…”

Section: Discussionmentioning

confidence: 73%

Effect of octreotide on glucose tolerance in acromegaly

Koop

Harris

Ezzat

1994

European Journal of Endocrinology

View full text Add to dashboard Cite

To determine the effect of the somatostatin analog octreotide on glucose tolerance in acromegaly, we examined glucose profiles, oral glucose tolerance and the insulinogenic index in patients treated with this analog. Ninety patients participated in a long-term, prospective, open-label study. There was no significant change between mean daily blood glucose profiles at baseline or during octreotide treatment. Using glucose tolerance test criteria, 61% of 90 patients had normal baseline glucose tolerance. While on octreotide, 20% and 29% of these patients, respectively, developed impaired glucose tolerance or became frankly diabetic. Conversely, three of the patients who were diabetic at baseline (N = 11) became normal (18%) or developed impaired glucose tolerance (9%) during octreotide therapy. There was no relationship between the dose of octreotide and change in glycemic state. The insulinogenic index (insulin/glucose) response to a glucose challenge decreased uniformly in octreotide-treated patients. Female patients and those with elevated baseline insulin levels were more likely to develop diabetes mellitus during octreotide therapy. In conclusion, octreotide significantly alters glucose tolerance in patients with acromegaly, mandating glucose monitoring during this form of therapy.

show abstract

Section: Discussionmentioning

confidence: 73%

Effect of octreotide on glucose tolerance in acromegaly

Koop

Harris

Ezzat

1994

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…A reduction in daily insulin dose of up to 50% was required in many Octreotide-treated insulin-dependent diabetics [1][2][3][4] and physiologically, Sandostatin LAR may affect glucose regulation in a similar manner. Therefore, hypoglycemic episodes may occur 10-14 days after the initial Sandostatin LAR injection if insulin dose is not reduced especially in patients with desirable glycemia.…”

Section: Discussionmentioning

confidence: 99%

“…Short acting Octreotide has been demonstrated to render uniformity to diurnal glycemia in Type 1 diabetes mellitus via inhibition of glucagon and human growth hormone as well as reduction of carbohydrate absorption [1][2][3][4][5][6][7][8]. Therefore, long acting octreotide (Sandostatin LAR) is likely to exert a similar effect in type 1 diabetes mellitus.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of sandostatin LAR in type 1 DM; improvement in glycemic control with less insulin. a case report

Bonucchi¹,

Lilli²,

Kabadi³

2011

JDM

View full text Add to dashboard Cite

Objective: Octreotide three times daily is reported to reduce daily insulin by 50% in patients with Type 1 DM. Therefore, we assessed the impact of long acting Octreotide (Sandostatin LAR) monthly intramuscular administration in a subject with Type 1 DM. Methods: A 32-year-old man with Type 1 DM of 16 years participated after obtaining informed consent. He had no microvascular or macrovascular complications. He continued the present insulin regimen for four weeks. IM Sandostatin LAR 20 mg was initiated and increased at four weeks to 30 mg. He was followed every four weeks for six months. Insulin regimen was adjusted every one to two weeks based on blood glucose before meals, bedtime and on onset of hypoglycemic symptoms. He continued other medications, previous diet and activity. Assessment of HbA1c, serum electrolytes, urea nitrogen, creatinine, TSH, free T4, liver enzymes, complete blood cell counts, vitamin B12, lipids and insulin regimen were performed at the initiation and end of the study. Results: HbA1c declined from 9 to 8% with reduction in daily insulin dose from 55 to 43 units, with a major reduction in insulin Glargine, 50 to 40 units. Body weight remained unaltered. Other laboratory tests including gallbladder examination remained unchanged Conclusion: Monthly Sandostatin LAR administration may improve glycemic control with less insulin in Type 1 DM.

show abstract